Sage Therapeutics Q2 EPS $(1.70) Misses $(1.66) Estimate, Sales $8.65M Miss $8.85M Estimate
Author: Benzinga Newsdesk | July 31, 2024 04:14pm
Sage Therapeutics (NASDAQ:
SAGE) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.66) by 2.41 percent. This is a 36.57 percent increase over losses of $(2.68) per share from the same period last year. The company reported quarterly sales of $8.65 million which missed the analyst consensus estimate of $8.85 million by 2.19 percent. This is a 249.80 percent increase over sales of $2.47 million the same period last year.
Posted In: SAGE